National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation
C Dai, RS Stafford, GC Alexander - Archives of internal medicine, 2005 - jamanetwork.com
Background The withdrawal of rofecoxib has highlighted concerns regarding the safety of
cyclooxygenase-2 (COX-2) inhibitors. In some patients COX-2 inhibitors may be safer than
nonselective nonsteroidal anti-inflammatory drugs (NSAIDs); however, the public health
benefit of COX-2 inhibitors depends on their use in patients at higher than normal risk from
NSAIDs. We examined trends in COX-2 inhibitor use based on risk for adverse events from
NSAIDs. Methods We analyzed data from the National Ambulatory Medical Care Survey …
cyclooxygenase-2 (COX-2) inhibitors. In some patients COX-2 inhibitors may be safer than
nonselective nonsteroidal anti-inflammatory drugs (NSAIDs); however, the public health
benefit of COX-2 inhibitors depends on their use in patients at higher than normal risk from
NSAIDs. We examined trends in COX-2 inhibitor use based on risk for adverse events from
NSAIDs. Methods We analyzed data from the National Ambulatory Medical Care Survey …
